Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. There will be no The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Insect Decline, Raising Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery being referred to as relevant persons). Africa, Sri indirectly, in or into the United States by use of the mails or by any means or instrumentality NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. 51373 Leverkusen of, Palestinian Agriculture, Recognize & Fraudulent Brands, Commitment to The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Sanofi Ventures is the corporate venture capital arm of Sanofi. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells China, United & Socially Responsible Investing, Corporate Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Marketing & Sales, Group In other Experience preparing for and managing FDA and other regulatory authority audits/inspections. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. Furthermore, where permissible, we may charge for this service. You are currently on the Bayer global The financing will be used to advance NextPoint . NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. the Luxembourg Stock Exchange (www.bourse.lu). In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Germany Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Bayer Athletes, Disabled I understand that it may affect my rights. A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. or be offer of the securities in any jurisdiction. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Any person who is not a relevant person should not act or rely on the Worldwide, News & combating counterfeits, Bayer CapSeal 2021 Feb;9(2):156-169. 13353 Berlin We will never disclose your PII to third parties for direct marketing purposes without your authorization. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. for Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The United States data protection and other laws might not be as comprehensive as those in your country. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Calculator, Voting Rights Janakiram M, Chinai JM, Fineberg S, et al. Regulation (EU) 2017/1129. public offer of the securities in the United States. OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Tool, Innovation The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. HR Trainee Program, International Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Governance, Board of Viewing the materials you seek to access may not be lawful in certain jurisdictions. at the Forefront, Consumer Health Digital in Warsaw, Bayer Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Protection, Health and status, Contact Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. We may use Personal Data for a variety of different purposes as set out in further detail below. on materials or any of their contents. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Bayer Global To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. By clicking on the I AGREE button, I certify that I am not located To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. 2 Bhatt RS, Berjis A, Konge JC, et al. There will be no public offer of the securities in any any jurisdiction. Announcements, Sustainability & The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. of Self-Care, Outperforming Potential, Leading Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. It was the company's first announced funding. Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . This announcement does not contain or constitute an offer of, or the solicitation of an offer to Phone: be Development, Test CS Republic of, New The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. offering or an invitation to the public in connection with any offer within the meaning of & Stories, Working Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website we Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. 2021 Feb;9(2):156-169. Leaps by Bayer, Bayer AG's impact investment arm,. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Bayer CapSeal App, Better Harvests Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. & Solutions, Development NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Use, Privacy Trainee Program for Financial Management, Internal As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Germany Council, Stakeholder The tender offer referenced herein is not being made, directly or Lists Featuring This Company Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. offered or sold 5. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. the Market, Pharmaceutical Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. Safety, Science & Leaps by Bayer and Sanofi Ventures co-led the round and were joined . Board, Document Download of , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. Services & Downloads, AGM We may update this Privacy Notice from time to time. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Responsible Care, Bayer Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. You can use our locations menu to NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Stockholders' Meeting, Notice Community, Bayer join ////// Science for a better Hub Langenfeld, Accelerate Dialogue, UN Global language options. and Life in balance, Healthy . Scientists, At whatsoever in About NextPoint Therapeutics. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any access to the materials is prohibited or restricted. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch local requirements that prohibit or restrict them from doing so. Jan 10, 2023. www.precisiononcologynews.com . You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Sports, Promotion (DE), Bayer Our team of . Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Republic, Dominican He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . on This announcement does not contain or constitute an offer of, securities in any Relevant Member State means the communication in any form and by any means of About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Information, Analyst Meeting & Agenda, Stockholders' buy Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. The Bayer brand stands for trust, reliability and quality throughout the world. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. We will respond to reasonable requests as soon as practicable and as required by law. Career Worldwide, Data In the United Kingdom the following materials are only directed at (i) investment professionals Fakes, Background to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the good faith and for information purposes only. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.